These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2658785)

  • 1. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate.
    Collette N; van der Auwera P; Lopez AP; Heymans C; Meunier F
    Antimicrob Agents Chemother; 1989 Mar; 33(3):362-8. PubMed ID: 2658785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients.
    Collette N; Van der Auwera P; Meunier F; Lambert C; Sculier JP; Coune A
    J Antimicrob Chemother; 1991 Apr; 27(4):535-48. PubMed ID: 1856132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.
    Souza LC; Campa A
    J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elution of High Dose Amphotericin B Deoxycholate From Polymethylmethacrylate.
    Houdek MT; Greenwood-Quaintance KE; Morrey ME; Patel R; Hanssen AD
    J Arthroplasty; 2015 Dec; 30(12):2308-10. PubMed ID: 26162513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.
    Clemons KV; Stevens DA
    J Antimicrob Chemother; 1992 Sep; 30(3):353-63. PubMed ID: 1452501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.
    Lignell A; Löwdin E; Cars O; Sjölin J
    J Antimicrob Chemother; 2008 Jul; 62(1):142-8. PubMed ID: 18408237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B.
    Chang T; Olson JA; Proffitt RT; Adler-Moore JP
    Med Mycol; 2010 Mar; 48(2):430-5. PubMed ID: 20141377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
    Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
    Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B lipid complex.
    Rapp RP; Gubbins PO; Evans ME
    Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.
    Groll AH; Mickiene D; Petraitis V; Petraitiene R; Alfaro RM; King C; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3917-25. PubMed ID: 14638502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
    Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
    Antimicrob Agents Chemother; 2002 Mar; 46(3):828-33. PubMed ID: 11850268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of different amphotericin B formulations from PMMA bone cements and their activity against Candida biofilm.
    Czuban M; Wulsten D; Wang L; Di Luca M; Trampuz A
    Colloids Surf B Biointerfaces; 2019 Nov; 183():110406. PubMed ID: 31401462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.
    Echevarría I; Barturen C; Renedo MJ; Trocóniz IF; Dios-Viéitez MC
    Antimicrob Agents Chemother; 2000 Apr; 44(4):898-904. PubMed ID: 10722488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies.
    Schulenburg A; Sperr W; Rabitsch W; Knöbl P; Thalhammer F
    Leuk Lymphoma; 2005 Aug; 46(8):1163-7. PubMed ID: 16085557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.
    Lee JW; Amantea MA; Francis PA; Navarro EE; Bacher J; Pizzo PA; Walsh TJ
    Antimicrob Agents Chemother; 1994 Apr; 38(4):713-8. PubMed ID: 8031034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
    Denning DW; Warn P
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2592-9. PubMed ID: 10543734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
    López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
    Garbino J; Markham L; Matulionyte R; Rives V; Lew D
    Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.